Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Vyndaqel
Pharma
BridgeBio CEO shrugs off recent Attruby pricing pressure fears
BridgeBio has laid out its expectations on potential generic pricing pressure for Attruby and provided more evidence of the drug's strong launch.
Kevin Dunleavy
Feb 25, 2026 2:30pm
BridgeBio shares slide on Pfizer's ATTR patent withdrawal
Feb 6, 2026 10:50am
Pfizer's challenge of BridgeBio ads referred to federal agencies
Nov 10, 2025 11:15am
Pfizer to discontinue low-dose ATTR drug Vyndaqel in US in 2025
Aug 29, 2025 10:40am
Alnylam's market cap jumps past $50B
Aug 1, 2025 7:39am
Alnylam's Amvuttra off to promising start in ATTR-CM
May 1, 2025 11:46am
